Neoadjuvant FOLFIRINOX improves outcomes
Neoadjuvant FOLFIRINOX improves outcomes, Published online: 22 May 2018; doi:10.1038/s41571-018-0043-xNeoadjuvant FOLFIRINOX improves outcomes (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - May 22, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Genomics reveals distinct gastric cancer subtypes
Genomics reveals distinct gastric cancer subtypes, Published online: 22 May 2018; doi:10.1038/s41571-018-0044-9Genomics reveals distinct gastric cancer subtypes (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - May 22, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
CTCs and benefit from radiotherapy
CTCs and benefit from radiotherapy, Published online: 21 May 2018; doi:10.1038/s41571-018-0042-yCTCs and benefit from radiotherapy (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - May 21, 2018 Category: Cancer & Oncology Authors: David Killock Source Type: research
Clinical utility of circulating non-coding RNAs — an update
Clinical utility of circulating non-coding RNAs — an update, Published online: 21 May 2018; doi:10.1038/s41571-018-0035-xEvidence of the functional roles of non-coding RNAs in cancer is expanding, and the potential of these RNAs as diagnostic and prognostic biomarkers is increasingly recognized. Herein, the authors review the recent developments in these areas and provide compendiums of circulating microRNAs and long non-coding RNAs that have promise as diagnostic and prognostic cancer biomarkers. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - May 21, 2018 Category: Cancer & Oncology Authors: Simone Anfossi Anna Babayan Klaus Pantel George A. Calin Source Type: research
Evolution of CLL treatment — from chemoimmunotherapy to targeted and individualized therapy
Evolution of CLL treatment — from chemoimmunotherapy to targeted and individualized therapy, Published online: 18 May 2018; doi:10.1038/s41571-018-0037-8In recent years, a number of novel agents have been added to the therapeutic armamentarium for patients with chronic lymphocytic leukaemia (CLL). Herein, Jan A. Burger and Susan O’Brien outline the emerging paradigm of individualized therapy for patients with CLL aimed at exploiting the advantages of these novel agents but also integrating traditional therapies for selected patients. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - May 18, 2018 Category: Cancer & Oncology Authors: Jan A. Burger Susan O ’Brien Source Type: research
Only the best CAR T cells
Only the best CAR T cells, Published online: 14 May 2018; doi:10.1038/s41571-018-0039-6Only the best CAR T cells (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - May 14, 2018 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
Low-value approvals and high prices might incentivize ineffective drug development
Low-value approvals and high prices might incentivize ineffective drug development, Published online: 14 May 2018; doi:10.1038/s41571-018-0030-2Drug regulators’ acceptance of any statistically significant improvement shown in a single randomized trial and lofty drug prices has created a situation where it is now, hypothetically, profitable for a company to run a clinical trials portfolio of chemically inert compounds. While the current cancer drug pipeline is certainly superior to inert drugs, we must rethink market incentives to encourage transformational drug development. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - May 14, 2018 Category: Cancer & Oncology Authors: Vinay Prasad Christopher McCabe Sham Mailankody Source Type: research
Poziotinib for uncommon ERBB mutations
Poziotinib for uncommon <i>ERBB</i> mutations, Published online: 09 May 2018; doi:10.1038/s41571-018-0038-7Poziotinib for uncommon ERBB mutations (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - May 9, 2018 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
Sustainability and affordability of cancer drugs: a novel pricing model
Sustainability and affordability of cancer drugs: a novel pricing model, Published online: 07 May 2018; doi:10.1038/s41571-018-0027-xThe affordability of newly approved anticancer agents is a challenge to many national health services and reimbursement systems. Therefore, we have developed an approach based upon the adoption of a novel model of price setting and herein provide examples of how it might be implemented. This model is intended to alter the balance between social and economic entrepreneurship. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - May 7, 2018 Category: Cancer & Oncology Authors: Carin A. Uyl-de Groot Bob L öwenberg Source Type: research
Pembrolizumab synergizes with chemotherapy
Pembrolizumab synergizes with chemotherapy, Published online: 03 May 2018; doi:10.1038/s41571-018-0031-1Pembrolizumab synergizes with chemotherapy (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - May 3, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Treatment resistance in urothelial carcinoma: an evolutionary perspective
Treatment resistance in urothelial carcinoma: an evolutionary perspective, Published online: 02 May 2018; doi:10.1038/s41571-018-0026-yPatients with advanced-stage urothelial carcinoma typically receive chemotherapy and might also receive immune-checkpoint inhibitorsfollowing disease progression. However, the majority of patients will ultimately develop resistance to treatment. In this Review, the authors describe the evolutionary mechanisms of treatment resistance in patients with urothelial carcinoma. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - May 2, 2018 Category: Cancer & Oncology Authors: Panagiotis J. Vlachostergios Bishoy M. Faltas Source Type: research
Author Correction: Analysis of DNA methylation in cancer: location revisited
Author Correction: Analysis of DNA methylation in cancer: location revisited, Published online: 30 April 2018; doi:10.1038/s41571-018-0028-9Author Correction: Analysis of DNA methylation in cancer: location revisited (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - April 30, 2018 Category: Cancer & Oncology Authors: Alexander Koch Sophie C. Joosten Zheng Feng Tim C. de Ruijter Muriel X. Draht Veerle Melotte Kim M. Smits Jurgen Veeck James G. Herman Leander Van Neste Wim Van Criekinge Tim de Meyer Manon van Engeland Source Type: research
Nivolumab–ipilimumab — exploiting the mutation burden of NSCLCs
Nivolumab–ipilimumab — exploiting the mutation burden of NSCLCs, Published online: 27 April 2018; doi:10.1038/s41571-018-0034-yNivolumab–ipilimumab — exploiting the mutation burden of NSCLCs (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - April 27, 2018 Category: Cancer & Oncology Authors: David Killock Source Type: research
Neoadjuvant PD-1 blockade in NSCLC
Neoadjuvant PD-1 blockade in NSCLC, Published online: 26 April 2018; doi:10.1038/s41571-018-0032-0Neoadjuvant PD-1 blockade in NSCLC (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - April 26, 2018 Category: Cancer & Oncology Authors: David Killock Source Type: research
Tracing the steps of cancer evolution
Tracing the steps of cancer evolution, Published online: 26 April 2018; doi:10.1038/s41571-018-0033-zTracing the steps of cancer evolution (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - April 26, 2018 Category: Cancer & Oncology Authors: Conor A. Bradley Source Type: research
